December 2012 Issue of MMM
December 2012 issue
If ever an industry could use four years of things staying basically the same, it's pharma
After a tumultuous few years of healthcare policymaking, the recent election brought a big victory for Obamacare. Expect this status quo to be anything but ...
With some of the biggest patent expiries due to pass in 2013, the next two years will be important in terms of pharma's return to ...
Spotlighting 196 agents, with profiles on 15 advances vying to be better, safer or cheaper than standard of care. Marc Iskowitz reports
Kerri Sparling, Writer/editor, Six Until Me
In 2012, the phrase "pharmaceutical marketing research" seems a little wrong
Energy drinks have been possibly linked to deaths and injuries. While there is no proof that the drinks caused these problems, there is reason to ...
Due to the trend toward increased healthcare access, healthcare could go from being an additional benefit to "being regarded everywhere as a basic human right." ...
Although Vivus weight loss drug Qsymia is getting a cold reception from regulators in the EU, where it is known as Qsvia, the company said ...
Sales of Amgen's Prolia are set to rise after a "soft" quarter, thanks to a sales force overhaul and an impending return to TV advertising, ...
News on Eli Lilly, Novartis, Johnson & Johnson and Pfizer
Med Ed Report
A new database aims to broaden the scope of insight that can be gleaned about doctors who tweet.
The Association of Clinical Researchers and Educators (ACRE) issued a code of conduct to guide doctors in what it considers major areas of interaction with ...
The American Medical Association adopted a change to its ethical policy on CME at the AMA House of Delegates meeting last month.
News on Vivus, India's income tax department, European Accreditation Council for CME and the Journal of General Internal Medicine
Nonprofit National Bureau of Economic Research—the organization that officially declares the stop and start of recessions—has issued a report that adds another angle to the ...
Starting next year, the BMJ will not publish academic papers on drugs or devices unless the relevant anonymized patient-level data are made available for third-party ...
News on Wiley, Nature Publishing Group and the American Society of Plastic Surgeons
The BMJ said it will not publish research papers on drugs when clinical trial data are kept secret. What effect will BMJ have on other ...
WebMD's third-quarter results showed that the health portal is still fighting for share.
To get moms to sign up for Text4Baby, there's the lure of a prize: enroll and you could end up with a lullaby written and ...
News on Pfizer, Manhattan Research and Treato
Sanofi has recruited actress Elizabeth Perkins, who has type 1 diabetes, to serve as the face of its Diabetes Co-Stars awareness campaign.
The latest example of Humira's command of DTC brand marketing can be seen in the campaign for its Crohn's disease indication.
Ten months after it was pulled due to manufacturing snafus, Novartis relaunched Excedrin with a celebrity spokesperson, migraine app and survey of women migraine sufferers.
The FDA issued a rare untitled letter concerning a pitch letter—a reminder that the agency does not consider press materials to be exempted from its ...
Consumer goods firm Reckitt Benckiser commenced a tender offer for vitamin and supplement company Schiff valued at $200 million more than an acquisition deal Schiff ...
News on AstraZeneca, Pew and Walgreens
Bristol-Myers Squibb is laying off close to 100 employees, including market researchers, as it recovers from patent expiries and awaits new approvals.
Pharma marketing researchers should provide actionable recommendations to brand managers and be more proactive in identifying opportunities to research business issues, said TGaS Advisors.
For the big mainline agencies, the creative consolidations at Pfizer and Johnson & Johnson are a big deal. But to their medical agency subsidiaries, the ...
Havas is merging two digital shops, Euro RSCG Life 4D and Creative Lynx, to form Havas Lynx
News on Roska Healthcare Advertising, Interpublic, Dudnyk and Lanmark 360
Major provisions in the FDA Safety and Innovation Act could make the approval process more transparent
FDA's drugs center wants to revisit a proposal once entertained by PhRMA to allow the agency access to all data from failed drug development programs ...
The FDA wants to replace Medication Guides, patient-package inserts, and other consumer medication information handed out at pharmacies with a proposed Patient Medication Information (PMIs) ...
Larry Mickelberg, Partner, Chief Digital Officer, Havas Heath/President, Havas Lynx US
There's a fine line between those who win the Gold and Silver Awards and those who don't. Here are a few MM&M Awards Finalists who ...
Jeremy Bender, Chief Business Officer, Sutro Biopharma
At Work With
Rob Perota, EVP, Executive Creative Director, Centron
The Medical Advertising Hall of Fame's "Young Executives' Night Out" offered some promising members of the agency world an informative seminar on how to grow ...
Name That Brand
Mechanics may have been instrumental in determining the outcome of the election
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.